Biotronik to Divest Vascular Intervention Division to Teleflex

In a significant move within the medical technology sector, Biotronik Group has entered into an agreement to sell its Vascular Intervention division to Teleflex Incorporated. This strategic divestment aligns with Biotronik's plans to streamline its operations, bolstering its position in core segments. The deal awaits regulatory clearance before it comes to fruition. Freshfields, a notable legal advisory firm, is championing this transaction on behalf of Biotronik, leveraging their extensive team across multiple global jurisdictions—highlighting their robust legal capabilities. Though Freshfields has not commented publicly on their involvement, the regional Counsellor Lukas Pomaroli based in Vienna, along with his team, is leading this venture.